Plasma Derived Therapies Market Status (2017-2021) and Forecast Market Analysis, Regional Outlook, Segment Growth Potential, and Competitive Market Share Analysis, 2022-2028
Report Description
The global Plasma Derived Therapies market size is estimated at USD 30,900.5 million in 2021, expanding at a CAGR 7.2% from 2022-2028 to reach USD 39,961.8 million USD in 2028.
Market Dynamics
Plasma-derived therapeutics are manufactured from human plasma rather than the synthetic or chemical components used to make most drugs. The rising frequency of immune deficiency disorders, autoimmune illnesses, neurological and bleeding illnesses are the primary drivers driving market growth. Along with these considerations, the global increase in the aging populations is a key driver of market expansion, since the old are more vulnerable to neurological illnesses.
Rising elderly population, growing frequency of genetic diseases, government efforts, growing adoption for albumin, expanding use of plasma in medicines, rising use of immunoglobulin, and booming autoimmune illnesses have all contributed to market expansion. Certain problems, such as high costs and rigorous regulations, are projected to confront the sector. To address these problems, the market will see technical developments, increasing supply for health insurance, increased usage of therapeutic protein medicines, and increased acceptance of plasma treatment in neurology.
Regional Insights
Throughout the projected period, North America is projected to lead the total plasma derived therapies market. The rising frequency and prevalence of immunological and neurologic illnesses are driving market expansion. The U.S is likely to be the region's main market. The well-established medical infrastructure-focused market participants on plasma protein therapies R&D, together with recent product releases and the growing burden of autoimmune illnesses, are main growth drivers for the market in the U.S.
The growing senior population in this region expands the patient pool, as the genetic population are more susceptible to neurological illnesses. Furthermore, beneficial government initiatives, consumer awareness levels between many blood donors, the availability of advanced protein fractionation procedures, lower per capita earnings in developed nations, and a rise in the number of collaborative research are some of the drivers anticipated to spur market growth in the region.
Segment Dynamics
Immunoglobulin has a greater market share in 2021. The immunoglobulins market is expected to expand due to increased use in primary health care and neurological applications. Grifols, S.A., a chemical and pharmaceutical business, for example, developed HyperHEP B in June 2021, a novel form of immune globulin derived from human blood for hepatitis B postexposure prophylaxis, moving the market ahead.
There is little known about plasma-derived medicines; nevertheless, the COVID-19 epidemic brought this sort of therapy to prominence and emphasized its potential uses. The primary stakeholders began conducting numerous research activities with the goal of identifying the utilization of plasma-derived therapies to treat COVID-19 infection. For example, in response to the disease outbreak in April 2020, major global players in the plasma-derived pharmaceuticals market, such as LFB, a pharmaceutical company specializing in biological therapeutic goods, formed the CoVIg-19 Plasma Alliance to encourage the growth of a hyperimmune immunoglobulin experimental therapy in the treatment of COVID-19.
Competitive Insights
The market for Plasma Derived Therapies is very competitive, with both domestic and international competitors. Large firms engage in strategic mergers and acquisitions, partnerships, and new product launches to remain competitive. Government efforts to assist the burgeoning renewable business, as well as an increase in mergers and acquisitions, have resulted in strong market competition. Biotest, for example, became Germany's first plasma protein producer to create an experimental hyper immunoglobulin preparation for COVID-19 in February 2021.
The report begins with an overview of the Industry Chain structure, and describes the industry environment, then analyses the market size and forecast of Plasma Derived Therapies by type, region, and application. In addition, this report introduces the market competition situation among the vendors, and company profile, besides, market price analysis, and value chain features are covered in this report.
Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products etc.):
- Takeda
- SK Plasma
- Shire
- Octaparma
- LFB
- Kedrion
- Grifols
- Fusion Healthcare
- CSL Behring LLC
- China Biologic Products Holdings Inc.
- Biotest
- Bio Products Laboratory (BPL)
- Bayer
- Baxter
- ADMA Biologics Inc.
Product Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):
- Albumin
- Immunoglobulin
- Factor VIII
- Others
Application Coverage (Market Size & Forecast, Main Consumer Analysis etc.):
- Hemophilia
- Idiopathic Thrombocytopenic Purpura
- Primary Immunodeficiencies
- Other Applications
Region Coverage (Regional Consumption, Demand & Forecast by Countries etc.):
- North America (U.S., and Canada)
- Europe (Germany, U.K., France, Italy, Spain etc.)
- Asia-Pacific (China, India, Japan, Indonesia, Malaysia, Australia, South Korea, etc.)
- South America (Brazil, Mexico, Argentina etc.)
- Middle East & Africa (Saudi Arabia, Kuwait, UAE, South Africa etc.)
Table Of Content
1. Plasma Derived Therapies Market Overview
1.1. Product Overview and Scope of Plasma Derived Therapies
1.2. Global Market Growth Prospects and Revenue Estimates
1.3. Global Plasma Derived Therapies Market Size Growth Rate Analysis by Product 2021 VS 2028
1.3.1. Albumin
1.3.2. Immunoglobulin
1.3.3. Factor VIII
1.3.4. Others
1.4. Global Plasma Derived Therapies Consumption Comparison by Application: 2021 VS 2028
1.4.1. Hemophilia
1.4.2. Idiopathic Thrombocytopenic Purpura
1.4.3. Primary Immunodeficiencies
1.4.4. Other Applications
1.5. Global Plasma Derived Therapies Market Size Estimates and Forecasts by Region: 2021 VS 2028
1.5.1. North America Plasma Derived Therapies Estimates
1.5.2. Europe Plasma Derived Therapies Estimates
1.5.3. China Plasma Derived Therapies Estimates
1.5.4. Japan Plasma Derived Therapies Estimates
2. Market Competition by Manufacturers
2.1. Global Plasma Derived Therapies Revenue Market Share by Manufacturers (2020)
2.2. Plasma Derived Therapies Market Share by Company Design (Tier 1, Tier 2 and Tier 3)
2.3. Global Plasma Derived Therapies Average Price by Manufacturers (2017-2021)
2.4. Manufacturers Plasma Derived Therapies Production Sites, Area Served, Product Types
2.5. Plasma Derived Therapies Market Competitive Situation and Trends
2.5.1. Plasma Derived Therapies Market Concentration Rate
2.5.2. Mergers & Acquisitions, Expansion
3. Global Plasma Derived Therapies Consumption by Region (2017-2021)
3.1. Global Plasma Derived Therapies Consumption by Region
3.2. Global Plasma Derived Therapies Consumption Market Share by Region
3.2.1. North America
3.2.2. North America Plasma Derived Therapies Consumption Growth Rate (2017-2021)
3.2.3. North America Plasma Derived Therapies Consumption, Price and Gross Margin (2017-2021)
3.2.4. North America Plasma Derived Therapies Consumption by Country
3.2.4.1. U.S.
3.2.4.2. Canada
3.2.5. Europe
3.2.6. Europe Plasma Derived Therapies Consumption Growth Rate (2017-2021)
3.2.7. Europe Plasma Derived Therapies Consumption, Price and Gross Margin (2017-2021)
3.2.8. Europe Plasma Derived Therapies Consumption by Country
3.2.8.1. Germany
3.2.8.2. U.K.
3.2.8.3. France
3.2.8.4. Italy
3.2.8.5. Spain
3.2.9. Asia Pacific
3.2.10. Asia Pacific Plasma Derived Therapies Consumption Growth Rate (2017-2021)
3.2.11. Asia Pacific Plasma Derived Therapies Consumption, Price and Gross Margin (2017-2021)
3.2.12. Asia Pacific Plasma Derived Therapies Consumption by Country
3.2.12.1. China
3.2.12.2. India
3.2.12.3. Japan
3.2.12.4. Indonesia
3.2.12.5. Malaysia
3.2.12.6. Australia
3.2.12.7. South Korea
3.2.13. South America
3.2.14. South America Plasma Derived Therapies Consumption Growth Rate (2017-2021)
3.2.15. South America Plasma Derived Therapies Consumption, Price and Gross Margin (2017-2021)
3.2.16. South America Plasma Derived Therapies Consumption by Country
3.2.16.1. Brazil
3.2.16.2. Mexico
3.2.16.3. Argentina
3.2.17. Middle East and Africa
3.2.18. Middle East and Africa Plasma Derived Therapies Consumption Growth Rate (2017-2021)
3.2.19. Middle East and Africa Plasma Derived Therapies Consumption, Price and Gross Margin (2017-2021)
3.2.20. Middle East and Africa Plasma Derived Therapies Consumption by Country
3.2.20.1. Saudi Arabia
3.2.20.2. Kuwait
3.2.20.3. UAE
3.2.20.4. South Africa
4. Global Plasma Derived Therapies Consumption by Product (2017-2021)
4.1. Global Plasma Derived Therapies Price by Product (2017-2021)
4.2. Global Plasma Derived Therapies Revenue Market Share by Product (2017-2021)
4.2.1. Albumin
4.2.2. Immunoglobulin
4.2.3. Factor VIII
4.2.4. Others
5. Global Plasma Derived Therapies Consumption by Application (2017-2021)
5.1. Global Plasma Derived Therapies Price by End User (2017-2021)
5.2. Global Plasma Derived Therapies Revenue Market Share by End User (2017-2021)
5.2.1. Hemophilia
5.2.2. Idiopathic Thrombocytopenic Purpura
5.2.3. Primary Immunodeficiencies
5.2.4. Other Applications
6. Key Companies Profiled
6.1. Takeda
6.1.1. Takeda Plasma Derived Therapies Corporation Information
6.1.2. Takeda Plasma Derived Therapies Product Portfolio
6.1.3. Takeda Plasma Derived Therapies Consumption, Price and Gross Margin (2017-2021)
6.1.4. Takeda Main Business and Markets Served
6.1.5. Takeda Recent Developments/Updates
6.2. SK Plasma
6.3. Shire
6.4. Octaparma
6.5. LFB
6.6. Kedrion
6.7. Grifols
6.8. Fusion Healthcare
6.9. CSL Behring LLC
6.10. China Biologic Products Holdings Inc.
6.11. Biotest
6.12. Bio Products Laboratory (BPL)
6.13. Bayer
6.14. Baxter
6.15. ADMA Biologics Inc
7. .Marketing Channel, Distributors and Customers
7.1. Marketing Channel
7.2. Plasma Derived Therapies Distributors List
7.3. Plasma Derived Therapies Customers
8. Market Dynamics
8.1. Plasma Derived Therapies Industry Trends
8.2. Plasma Derived Therapies Growth Drivers
8.3. Plasma Derived Therapies Market Challenges
8.4. Plasma Derived Therapies Market Restraints
9. Global Plasma Derived Therapies Consumption and Demand Forecast, by Region (2022-2028)
9.1. Global Forecasted Demand Analysis of Plasma Derived Therapies, by Regions and Country
9.1.1. North America Forecasted Consumption of Plasma Derived Therapies by Country
9.1.2. Europe Market Forecasted Consumption of Plasma Derived Therapies by Country
9.1.3. Asia Pacific Market Forecasted Consumption of Plasma Derived Therapies by Region
9.1.4. Latin America Forecasted Consumption of Plasma Derived Therapies by Country
9.1.5. Middle East and Africa Forecasted Consumption of Plasma Derived Therapies by Country
10. Global Plasma Derived Therapies Consumption and Demand Forecast, by Device Segments (2022-2028)
10.1. Global Forecasted Consumption of Plasma Derived Therapies by Device Segments (2022-2028)
10.2. Global Consumption and Price Forecast by Device Segments (2022-2028)
10.3. Global Forecasted Growth Rate of Plasma Derived Therapies by Device Segments (2022-2028)
11. Research Finding and Conclusion
12. Methodology and Data Source
12.1. Methodology/Research Approach
12.1.1. Research Programs/Design
12.1.2. Market Size Estimation
12.1.3. Market Breakdown and Data Triangulation
12.2. Data Source
12.2.1. Secondary Sources
12.2.2. Primary Sources
12.3. Author List
12.4. Disclaimer
Research Methodology
Our research studies are primarily performed in five phases which include Secondary Research, Primary Research, Subject Matter Expert Advice, Quality Check, and Final Review. The process opted for conducting thorough research to make authentic business reports is briefly described below-
Secondary Research-
- Based on the understanding of requirements, we conducted secondary research to identify the Segment specifications, qualitative and quantitative data along with the factors responsible for the growth of the market.
- The secondary sources referred for the study include press releases, company annual reports, and research papers related to the industry.
- Various sources such as industry magazines, trade journals, government websites, and associations were also reviewed for gathering precise analysis on opportunities for business expansions in the market.
- Moreover, quantitative as well as qualitative data were also extracted from paid databases, which included Reuters, Factiva, Bloomberg, One Source, and Hoovers, which proved to be useful for in-depth technical study of the market.
Primary Research-
- The research carried out during the desk research was verified by primary interviews. Primary research was scheduled with a number of industry experts for conducting telephonic interviews, and also our team send questionnaires through their official emails.
- The secondary data collected was then verified by various industry participants which included Segment managers, marketing managers, VPs, CEOs, purchasing managers, subject matter experts.
- An interview with the mentioned participants aids invalidation of our research findings regarding the Segment.
- It helps in the provision of first-hand data on factors such as market size, growth, regional trends, market trends, and competition in the industry. This approach makes our findings precise in order to help our clients in strategic decision-making processes.
Subject Matter Advice-
- The secondary and primary research key findings were then validated by the in-house subject matter experts having extensive experience in the market research industry.
- Specific requirements of the clients were reviewed by the experts to check for completion of the market study. Experts help in channelizing the representation skills of the analyst in terms of providing data that can be easily understood by our customers.
Quality Check-
- The analysis done by the research team was further reviewed to check for data accuracy provided to suit the clients’ specific requirements.
- This revision was done in various phases to check the data authenticity and to remove negligible errors in the final compilation.
Final Review-
- After the quality check, a final review of the report was done to look after the presentation, formatting, and to recheck if all the requirements of the clients were addressed. The next phase remains dispatch of the report to the client.
Enquire Before Purchase
Frequently Asked Questions
Why Choose Market Research Strategy?
We utilize market analysis/information from verified authenticated data sources to scoop accurate research reports
We understand the urgency of our clients and their clients' in the competitive space thus, deliver the report in minimum turnaround
Without further ado, choose us and get instant access to reliable analysis to help you make the right business decisions.
We abide by the information security policy and adheres to keep your private and business information confidential and secure.